Skip to content

CareDx CDNA Capital investments accrued but not yet paid

Capital investments accrued but not yet paid at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO

Other financials

Income statement

See full
Revenue$117.7M+39.0%
Operating income$1.2M+109%
Net income$2.8M+127%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$78.5M-12.1%
Total debt$24.5M-19.1%
Total equity$313.5M-17.3%
Total assets$411.1M-16.0%

Cash flow

See full
Operating cash flow$4.3M+116%
CapEx$3.8M+134%
Free cash flow$514.0K+102%

Valuation

See full
Market cap$1.4B+32.2%
Enterprise value$1.35B+34.6%
P/S3.4×+0.3×

Profitability

See full
Gross margin65.5%
Operating margin-3.9%-18.3pp
Net margin-2%-19.9pp
FCF margin-0%0.0pp

Returns & leverage

See full
Return on equity-2.4%-21.9pp
Debt / equity0.1×0.0×
Current ratio3.4×-0.7×

Where this comes from

Reported directly by CareDx in its filing.

Tagged under the XBRL concept us-gaap:CapitalExpendituresIncurredButNotYetPaid.

The official record: CareDx’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about CareDx's capital investments accrued but not yet paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CareDx's capital investments accrued but not yet paid?
CareDx (CDNA) reported capital investments accrued but not yet paid of $802.25K in Q4 2025.
How has CareDx's capital investments accrued but not yet paid changed year-over-year?
CareDx's capital investments accrued but not yet paid increased by 407.0% year-over-year, from $158.25K to $802.25K.
What is the long-term trend for CareDx's capital investments accrued but not yet paid?
Over 4 years (2021 to 2025), CareDx's capital investments accrued but not yet paid has grown at a -5.1% compound annual growth rate (CAGR), from $3.95M to $3.21M.